mTOR Modulation Affects Galectin-1 Expression in KMT2A -rearranged Acute Lymphoblastic Leukemia Cells
Anticancer Research · 2026
DOI: 10.21873/anticanres.17976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Bartłomiej Pawlik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, TOR Serine-Threonine Kinases, Galectin 1, Histone-Lysine N-Methyltransferase.
Abstract (Originalsprache)
BACKGROUND/AIM: Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Among its genetic subtypes, KMT2A (formerly MLL)-rearranged ALL (KMT2Ar-ALL) is associated with poor outcomes. Immunotherapy approaches are being studied and used in KMT2Ar-ALL; however, there is evidence that leukemic cells can escape immune control. Our previous study identified Galectin-1, an immune checkpoint protein, as highly expressed in KMT2Ar-ALL, suggesting it as a potential therapeutic target. To date, the exact mechanism of Galectin-1 regulation in KMT2Ar-ALL is unknown. Therefore, the present study aimed to investigate the potential involvement of the mTOR signaling pathway in the regulation of Galectin-1 expression in KMT2Ar-ALL. MATERIALS AND METHODS: The study employed both in silico and in vitro approaches: gene expression data from B-cell acute lymphoblastic leukemia subtypes were analyzed bioinformatically, while four leukemia cell lines (RS4;11, SEMK2, SUP-B15, and NB-4) were treated with the mTOR inhibitor everolimus to evaluate its effect on Galectin-1 expression at the mRNA and protein levels, using qPCR and immunoblotting. Transcription factor binding on the LGALS1 promoter was assessed with computational tools. RESULTS: Galectin-1 mRNA and protein were selectively upregulated in KMT2Ar-ALL cells, and inhibition of the mTOR pathway with everolimus modulated Galectin-1 expression in these cells. A novel putative transcription factor, SP1, was proposed, which may bind to the Galectin-1 promoter and can be regulated by the mTOR pathway. CONCLUSION: Targeting mTOR signaling contributes to the regulation of Galectin-1 immune checkpoint activity in KMT2Ar-ALL. Inhibition of mTOR may represent a potential therapeutic strategy to overcome immune evasion in this leukemia subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
- Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.
- Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
- Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland; wojciech.mlynarski@umed.lodz.pl.
Zitieren
APA
Pawlik, B., Madzio, J., Rydzyńska, Z., Mazurek, M., Grzela, D. P., Walenciak, J., & Młynarski, W. (2026). mTOR Modulation Affects Galectin-1 Expression in KMT2A -rearranged Acute Lymphoblastic Leukemia Cells. Anticancer Research. https://doi.org/10.21873/anticanres.17976
Vancouver
Pawlik B, Madzio J, Rydzyńska Z, Mazurek M, Grzela DP, Walenciak J, et al. mTOR Modulation Affects Galectin-1 Expression in KMT2A -rearranged Acute Lymphoblastic Leukemia Cells. Anticancer Research. 2026. doi:10.21873/anticanres.17976
BibTeX
@article{Pawlik2026,
author = {Pawlik, Bartłomiej and Madzio, Joanna and Rydzyńska, Zuzanna and Mazurek, Maciej and Grzela, Dawid P and Walenciak, Justyna and Młynarski, Wojciech},
title = {mTOR Modulation Affects Galectin-1 Expression in KMT2A -rearranged Acute Lymphoblastic Leukemia Cells},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.17976}
}
EUVIMED